A menopause study linked hormone therapy with greater semaglutide weight loss. See the results, study limits and questions for future trials.
On October 8, 2026, The Menopause Society announced findings linking menopausal hormone therapy (MHT) with greater weight loss among women taking semaglutide. Semaglutide is the active ingredient in Wegovy and Ozempic, according to Medical News Today. The retrospective observational study was presented at the society’s 2026 Annual Meeting in San Diego.
The society described nearly 2,400 women taking semaglutide and nearly 1,500 taking tirzepatide. Participants were over 45 and had a BMI above 27 kg/m². Researchers compared women using MHT with women who were not using it while taking either medication.
The pattern differed between the drugs. According to the society’s announcement, MHT use was associated with significantly greater and sustained weight loss in the semaglutide group. In the tirzepatide group, an initial advantage did not remain statistically significant at the end of the analysis.
The question has practical relevance in midlife care. The Menopause Society reports that approximately one in five U.S. women aged 50 to 64 say they currently use or have used a GLP-1-based obesity medication. That is broader context for the announcement, not a result from this hormone-therapy cohort.
The biological question behind the finding is whether menopausal hormone therapy influences the response to GLP-1-based medication. Study author Regina Castaneda of Mayo Clinic Florida suggested that differences in how the medications act on GLP-1 signaling could help explain the different findings.
In plain language, signaling is the way a biological message is passed along and acted upon. The proposed connection is that hormone therapy might relate to how that message is handled during treatment. Castaneda presented this as a possible explanation rather than an established mechanism.
The Menopause Society’s medical director, Stephanie Faubion, said hormone therapy “may influence how some women respond” to GLP-1-based medications. That frames a specific research question about treatment response. It is not a complete biological explanation for the weight changes recorded in the study.
Coverage in Medical News Today and U.S. News & World Report emphasizes the possibility that hormone therapy might improve GLP-1 weight-loss results. Their headlines use conditional language. Readers should still distinguish the appealing idea of a treatment combination from the narrower evidence reported.
The Menopause Society described a retrospective observational analysis. Researchers examined outcomes among women using different treatments rather than assigning hormone therapy to test its effects. That design identifies an association but does not establish that MHT caused the additional weight loss.
Medical News Today also noted gaps in the available detail. The coverage does not give exact MHT group counts, detailed baseline characteristics or the hormone regimens used. The work was described as a conference presentation. The cited coverage does not establish that the findings have undergone peer review.
Those missing details matter when asking whether the treatment groups were comparable before their outcomes were measured. Without a full account of who received which treatment, the size of the study does not resolve that question. A large dataset and a clear cause-and-effect answer are not the same thing.
The tirzepatide finding needs careful interpretation too. A nonsignificant result is not proof that MHT has no effect in that group. It is also not a basis for assuming that the semaglutide association applies equally to both medications.
The cited coverage does not provide treatment-specific safety results. Whether hormone therapy is appropriate for a particular person therefore remains a separate clinical decision.
Castaneda called the results “hypothesis-generating” and stressed that weight loss is not an indication for MHT. For someone considering hormone therapy for menopausal symptoms, the useful next step is a discussion of personal benefits and risks with a qualified clinician. This report alone is not a reason to start, stop or change either treatment.
It helps to keep two care questions separate. One concerns whether MHT is appropriate for menopausal symptoms. The other concerns how weight-management treatment is working. The study connects those topics for researchers without turning them into the same clinical decision.
Questions worth bringing to an appointment include:
WeightRestart’s discussion of menopause symptoms and hormone-therapy decisions provides related reading. Our focus is research-led, shame-free guidance rather than turning an early finding into a new requirement for successful weight management.
U.S. News & World Report supplied more specific semaglutide results from the study. At one year, average body-weight loss was about 11% among women taking MHT and 9.5% among those not taking it.
The report also described how many women reached a larger weight-loss outcome. At least 20% of body weight was lost by 22% of women taking MHT and 18% of women not taking it. These figures describe the semaglutide comparison.
These are different ways to summarize results. The average describes weight change across each group. The threshold result describes how many participants reached a particular amount of weight loss. Neither tells an individual where their own result will fall.
That makes the numbers useful for understanding the study rather than setting a personal target from a headline. The research asked how groups differed. A care discussion also needs to ask which outcomes matter for the person receiving treatment.
The word “sustained” in the society’s announcement deserves a careful reading. It describes the pattern observed during the analysis rather than a prediction of lifelong weight maintenance. Keeping the observation period attached to the finding helps prevent a broader claim than the evidence supports.
The reported percentages concern body weight rather than a breakdown of fat and lean mass. For readers considering how progress is described, WeightRestart’s guide to looking beyond the scale addresses that separate topic. Our body-neutral approach keeps the broader conversation focused on metabolic health and sustainable habits.
The next useful study should make the comparison easier to interpret. It should clearly describe hormone regimens and participants’ starting characteristics. It should also report semaglutide and tirzepatide outcomes separately rather than treating every GLP-1-based medication as one category.
Future research should look beyond which group lost more weight. Researchers should examine sustained outcomes and report treatment-specific safety. The question is whether any difference is meaningful enough to matter in care, not simply whether a headline can describe a larger number.
What to watch next is a well-designed prospective trial that tests whether the association holds when treatment use and follow-up are defined in advance. Castaneda has called for prospective confirmation before firm conclusions are drawn. Before this could inform standard practice, the evidence would need to clarify both the weight-loss benefit and the safety of the approach. The standard to look for is evidence that improves care decisions rather than another encouraging association.
WeightRestart shares research-led guidance on weight loss, metabolism, nutrition, strength, appetite, sleep and recovery. Our goal is to make complex health information clear, practical and useful for people building progress they can maintain.
Learn how to build a weight-management approach around better information, realistic expectations and habits you can keep using.
read the blog
